Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Clinical Pathways
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 46 Results
National Pharmaceutical Council and Duke-Margolis Center for Health Policy Announce New Health Policy Fellow
Dr. Salama Freed has been named NPC/Duke-Margolis Health Policy Fellow for 2020-22.
National Pharmaceutical Council 2019 Annual Report
NPC's 2019 annual report outlines how the organization is driving discussions on some of the most complex topics in health care policy.
Johnson & Johnson’s Blasine Penkowski Elected National Pharmaceutical Council Board Chair
NPC announced that Blasine Penkowski, MBA, Chief Strategic Customer Officer of Johnson & Johnson Health Care Systems Inc., has been elected Chair of NPC’s Board of Directors for 2019-2020.
National Pharmaceutical Council 2018 Annual Report
2018 marked NPC’s 65th anniversary as a leader in health research and policy.
National Pharmaceutical Council 2018 Annual Report
National Pharmaceutical Council's 2018 Annual Report detailed our 65th anniversary as a leader in health policy research, celebrating a continued focus on strong research to drive conversations on…
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?
In this study from the National Pharmaceutical Council and IQVIA, researchers developed a model to understand the underlying methodological inputs that drive the substantial variation in drug…
What's Been the Bang for the Buck? Cost-Effectiveness of Health Care Spending Across Selected Conditions in the US
This study was designed to assess whether increased medical intervention spending on prevalent chronic conditions has been a good investment over time.
Celgene EVP Richard Bagger Elected National Pharmaceutical Council Board Chair
The NPC Board of Directors has named Celgene EVP Richard Bagger as Chairman for 2018-19.
National Pharmaceutical Council 2017 Annual Report
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that…
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Concerns Around Budget Impact Thresholds: Not All Drugs Are The Same
A study published in Value in Health explores the potential impact of using budget thresholds as budget caps (e.g., cannot spend more than a set dollar amount) for individual drugs.
National Pharmaceutical Council 2016 Annual Report
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that…
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…
Why Is Broader Access to Publicly Funded Data Important?
This infographic illustrates the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers.
National Pharmaceutical Council 2015 Annual Report
NPC had an active 2015, publishing a number of research studies and speaking at conferences about important health topics.
What Contributes Most to High Health Care Costs?
A small segment of the population—often the sickest patients—drive the majority of health care spending. This study, which examined the spending patterns for these high resource patients (HRP), …
When Does FDAMA Section 114 Apply? Ten Case Studies
There is hesitation to disseminate comparative effectiveness research because of ambiguities in the law that was established to help biopharmaceutical companies engage health plans around real-world…
National Pharmaceutical Council 2014 Annual Report
The 2014 Annual Report highlights NPC's research, educational and partnership activities throughout the year.